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Background: Familial Mediterranean Fever (FMF), characterized by recurrent fever and inflammation of serous
membranes, is an autosomal recessive disease caused by mutations in the Mediterranean fever (MEFV) gene.
Around 296 mutations have been reported to date.
Methods: Two two-generation Turkish families with a total of four members diagnosed with FMF clinically were
screened with DNA sequencing performed on exon 2 and exon 10 of the MEFV genes. Then, complete exome
sequencing analysis of MEFV gene was done for four patients in whom novel mutation was detected.
Results: A novel single base Guanine (G) insertion mutation in the coding region of MEFV gene, named
c.2330dupG (p.Gln778Serfs*4 or Q778SfsX4) resulting in a mutated Pyrin/Marenostrin protein was identified.
Conclusions: This is the first report of a new mutation in exon 10 of the MEFV gene in two Turkish families. This
novel pattern of insertion mutation may provide important information for further studies on FMF pathogenesis.
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Familial Mediterranean Fever (FMF) is a hereditary auto
inflammatory disease, predominantly affecting people of
Mediterranean and Middle Eastern descent, especially
Jews, Turks, Armenians, Greeks and Arabs. It is cha-
racterized by recurrent attacks of fever, abdominal pain
with peritonitis, pleuritis, arthritis, skin lesions (erysip-
elas-like erythema) and renal amyloidosis [1,2]. Systemic
amyloid A (SAA) protein deposition especially in the
kidneys makes FMF a potentially fatal disease [1]. Since
clinical diagnosis is difficult, identification of disease
causing mutations is crucial [2].
The FMF gene is the Mediterranean FeVer (MEFV)
gene, comprises 10 exons, is located on the short arm of
chromosome 16 at position p13.3 and encodes for the
781 amino-acid protein named as pyrin or marenostrin
[2-4]. Disease-associated mutations have been identified;* Correspondence: dthdogan@gmail.com
1Department of Medical Biology, Medicine Faculty, Ataturk University, 25240
Erzurum, Turkey
Full list of author information is available at the end of the article
© 2014 Dogan et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.comprised approximately 85% of the mutations in exon
10 and exon 2 [5]. To date, more than 296 gene muta-
tions and polymorphisms have been discovered in the
gene [6]. Still new mutations and their association with
FMF are understudied. Among these mutations, there is
only one insertion mutation on exon 2 that was reported
in 2002 [6].
Generally FMF is inherited in an autosomal recessive
manner, but recent studies have showed that some cases
that are heterozygotes can manifest a clinical symptom
consistently with mild FMF [7].
In this study, four patients with FMF symptoms who
have two ancestries with a single base Guanine (G)
insertion/duplication mutation on exon 10 were showed.Methods
Subjects
Each year, approximately 1200 clinically pre-diagnosed
FMF cases are referred to our laboratory by their physi-
cians to detect MEFV mutations. Among those patients
with clinical evidence for FMF, 4 individuals from twoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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study approved by the local institutional review board
and ethics committee of Ataturk University, Medical
Faculty, Erzurum, Turkey (no. B.30.2.ATA.0.01.00/63).
Informed consent for the publication of this data was
obtained from participants or their parents for the indi-
viduals under 18 years old.
PCR amplification and sequencing
From each patient, 2 cc peripheral venous blood specimens
were collected in test tubes containing anti-coagulant
(EDTA). Genomic DNA was isolated with an automatized
DNA isolation device (MagNA Pure LC DNA Isolation
Kit I, Roche) according to manufacturer’s instructions.
Exon 2 and exon 10 was sequenced by using GML Seq-
Finder Sequencing System MEFV kit and confirmation
sequenced was done by the following primers Exon 2: F:
5′-CTAAACGTGGGACAGCTTCATC-3′ and R: 5′-CT
TCCTTCAGGTCCGCAGAT-3′; Exon 10: F: 5′-GAC
TTGGAAACAAGTGGGAGAG-3′, and R: 5′-CAGGAA
GAGAGATGCAGTGTTG-3′ using Sanger sequence
technology. PCR conditions were as follows: Initial de-
naturation at 94°C for 5 minutes, 35 cycles at 94°C for
30 seconds and 58°C for 45 seconds, 72°C for 1 minute,
and a final extension at 72°C for 5 minutes. The PCR
products were visualized and collected with 2% agarose gel
electrophoresis followed by purification using Exo-SAP
PCR purification Kit (UAB Corporation, Cleveland, Ohio,
USA) The product was sequenced in both strands initia-
ting from the forward and the reverse primers used in the
initial PCR and analysed on an ABI 3130 Automated DNA
Sequencer (Applied Biosystems, Foster City, CA, USA).
Further analysis was performed with SeqScape v2.6 and
Sequencing Analysis 5.3.1 version programs.
We checked the whole coding region to search for a
mutation on the second MEFV allele although there were
4 individuals with novel MEFV mutation in the heterozy-
gous state. Whole exome MEFV gene sequencing of four
patients in whom novel mutation was performed with the
454 GS-Junior Next Generation Sequencer platform
(Roche Diagnostics, Mannheim, Germany), according to
manufacturers’ instructions. Analysis was performed with
JSI Medical Systems in SeqNext Software (Roche Diagnos-
tics, Mannheim, Germany) programs.
In both sequence analyses, the reference coding se-
quence of the wild-type MEFV was obtained from the
NCBI, Gene Bank accession number AF111163 (FMF;
OMIM no. *249100) (http://www.ncbi.nlm.nih.gov/).
Results
Two unrelated patients aged 16 and 7, who were clini-
cally suspected of FMF with mild symptoms of recurrent
attacks of fever (1-3 days) and abdominal pain were re-
ferred separately to our laboratory by their physiciansfor routine analysis of MEFV mutation detection. In
both patients a heterozygous single G nucleotide du-
plication resulting in frame shift mutation in exon 10 at
777th codon, (between 2330th and 2331st nucleotides)
was detected (Figure 1). The frame shift mutation was
confirmed by sequencing in both directions. Next, DNA
samples from first-degree relatives of the two patients
(4 individuals from each family, 8 subjects totally) were
collected to screen for mutations at exon 2 and exon 10.
Although no variations were detected by whole exome
sequencing of all 10 exons of MEFV gene in 4 indi-
viduals from each family, the mothers of both patients
have the same heterozygous frame shift mutation as the
patients (Table 1). The pedigrees of the families and the
mutations that were found are shown in Figure 2. Due
to the G nucleotide insertion and frame shift mutation
between 2330th and 2331st, the nucleotide sequence con-
verted from ggt cag ggg cct gac tga to ggG tca ggg gcc
tga and this conversion resulted in a stop at codon 780.
The protein sequence converted from Gly-Gln-Gly-Pro-
Asp-STOP to Gly-Ser-Gly-Ala-STOP (p.Gln778Serfs*4
or Q778SfsX4).
On six different mutation analyser web-based tools,
c.2330dupG mutation was searched. Align GVGD
and PolyPhen-2 (HumDiv Prediction version) showed
c.2330dupG mutation might have pathogenic effect
(Table 2) [8-13].
The patients did not fulfil the major criteria of FMF
disease, although they both showed mild symptoms of
minor criteria (recurrent abdominal pain and recurrent
attacks of fever) (Table 1). Detailed information about
the two patients and their families is as follows:
Family A
16-year-old male (Child 1) with mild FMF symptoms and
arthritis. c.2330dupG mutation was detected with DNA
sequencing. After screening the family, the mother; whose
suffered mild symptoms of recurrent attacks of fever (1-3
days) and abdominal pain also, was found to have the
same insertion as patient A.
Family B
7-year-old male (Child 1) with mild FMF symptoms
having a sibling diagnosed with FMF and an asympto-
matic father carrying the heterozygous common muta-
tion V726A. Because the family has another child with
FMF and they know that they are carriers, child 1 was
admitted by us early for genetic testing. The mother is a
carrier of M694V, showing the symptoms of chest pain,
recurrent abdominal pain and recurrent fever. Upon
testing by DNA sequencing, heterozygous c.2330dupG
was detected in Child 1. Also his mother has been de-
tected as compound heterozygous due to both M694V
and c.2330dupG mutations.










Abd. pain Fever Chest pain Arthritis Skin lesions Amyloidosis
Family A Father M, 41y No Sx* wt** - - - - - -
Mother F, 35y 30y c.2330dupG/0 + + - - - -
Child 11 M, 16y 15y c.2330dupG/0 + + - + - -
Child 2 F, 10y No Sx wt** - - - - - -
Family B Father M, 35y No Sx V726A/0 - - - - - -
Mother F, 32y 20y c.2330dupG/M694V + + + - - -
Child 11 M, 7y 6y c.2330dupG/0 + + - - - -
Child 2 M, 10y 3y M694V/V726A + + - - - -
No Sx*: No Symptoms; wt**: Wild type; 1: Probands.
Figure 1 Electrophoregrams of the new heterozygous insertion at 2331st nucleotide of MEFV. The insertion resulted frame shift in codon
777. (a) Forward Electrophoregram, (b) Reverse Electrophoregram.
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Figure 2 Pedigree diagrams of the probands families.
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In this study, we report a novel frame shift mutation of
the MEFV gene; c.2330dupG that was detected in 4 FMF
patients in 2 families from eastern Turkey. The suppor-
ting findings which analysed from different web-based
online tools, and outcomes from the patients whom are
subject of this article whether this novel mutation causes
FMF and may have genotype/phenotype correlations are
as follows: Firstly, c.2330dupG mutation was found in
patients with clinical symptoms characteristic for FMF
and it has not been found in any of the subject MEFV
genes from unaffected Turkish inhabitants so far among
the regional 2,530 referrals, 1,048 cases (41.42%) of themTable 2 Results of mutation analyser web-based tools
Computational pathogenicit
Prediction Score 1







http://sift.jcvi.org/ [11] Tolerated 0.1
http://provean.jcvi.org/seq_submit.php [12] Neutral -1.027
http://www.mutationtaster.org/ [13] Polymorphismhad the known mutations of MEFV [14]. Secondly, the
mother of Family B is a carrier with M694V common
mutation, which is one of the best-characterized muta-
tions known to cause FMF in a recessive manner. In
addition to this, she is also heterozygous for c.2330dupG
mutation and she also has mild FMF symptoms. There-
fore, we think that the insertion mutation probably
caused FMF disease by compound heterozygousity.
Thirdly, this novel mutation was found in exon 10 of
MEFV, where most mutations that are identified as FMF
causing mutations are located. The structure of the
C-terminal domain has been described, although this
very C-terminal region in which our insertion residesy predictions
Score 2 Score 1&2 description
68.20 (GV, GD) Prediction ranges from C0-benign to
C65- pathogenic
3. 08 SIFT Score. Ranges from 0 to 1. The amino acid
substitution is predicted damaging is the score is < = 0.05,
and tolerated if the score is > 0.05.
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B30.2 domain is also named the PRYSPRY domain and
has the functions of ligand binding, signal transduction
and mediating protein–protein interactions. The muta-
tions may diminish or eliminate the ability of pyrin, con-
sequently suppressing apoptosis and IL-1B activation
[16,17]. The novel mutation is very near to the end of
the C-terminal, after the B30.2 domain and there are 5
amino acids after this position. We made a model of this
area of pyrin protein in 3D diagrams using web-based
protein structure prediction databases, but the exact
effect of this area is not understood (Figure 3) [18]. So
far 3 different missense mutations have been described
in this C-terminal region, although only one of them
was reported as symptomatic [6]. Mutations at this loca-
tion have potential roles on the function this protein.
Recent findings indicate the clinical disease with he-
terozygous mutations of MEFV gene and thus these
mutations may act as dominant negative mutations or
pseudo-dominantly (Manifesting heterozygousity FMF;
OMIM no. *134610) [7,19,20]. Although the mother in
family A and two probands are associated with mild
FMF symptoms, they are heterozygous. Therefore, the
insertion mutation presented in this article may cause
FMF disease by dominant inheritance. Further molecular
biology studies should have been done to proof this. The
ratio of patients with a single mutation varies between
16.5% and 33.8% for FMF. These mutations clinically
caused mild inflammatory process [21,22]. Marek-Yagel
et al. [20] and van Gijn et al. [23] tried to discover a
second mutation on the second allele in the MEFV gene
of heterozygous patients by investigating the coding re-
gion, the exon and intron boundaries, as well as in the
promoter region of the gene. Although they performed
complete sequencing of the gene, they were unable toFigure 3 3D view of pyrin protein [18].detect a second mutation. Later, it became obvious that
FMF is not fully recessive and that in some cases hete-
rozygous mutations are associated with mild clinical
symptoms. A complete sequencing of all 10 exons of the
MEFV gene in four individuals’ carriers of a novel muta-
tion did not show the presence of a second pathogenic
mutation. We can therefore conclude that the sympto-
matic two probands and the mother of family A are true
heterozygous and the mother of family B is compound
heterozygous as she has got both M694V and c.2330dupG
mutations. Based on these findings and our own, we can
say that the simple heterozygous insertion mutation can
cause FMF disease.
The novel mutation was present in a heterozygous
state in four subjects, located in exon 10 of the gene and
causes amino acid replacement after the 777th amino
acids. This mutation caused a new amino acid sequence
that is G777G, Q778S, G779G, P780A and D781stop;
and shortened one amino acid. This novel frame shift
mutation is found in exon 10 of MEFV gene, where pre-
viously identified FMF causing mutations are located.
A frame shift mutation involves the insertion or dele-
tion of a nucleotide in which the number of deleted base
pairs that is not a multiple of three and consequently
disrupt the triplet reading frame, generally leading to the
formation of premature termination (STOP codon) and
resulting in a truncated protein product. To date for FMF
two ‘in frame’ deletion mutations have been described,
I692del and M694del. So far, no insertion has been reported
at exon 10. At exon 2, four insertions have been reported,
334_335insG (p.Glu112fs*130), 390_391insGAGGGGAAC
(p.Glu128_Asn130dup), 606_621dup (p.Ser208Alafs*39)
and 761_764dupCCGC (p.Asn256Argfs*70) [1,6,24]. Only
one of these is a single G base insertion as it is in our cases.
No frame shift mutations have been described at other
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cant because it is the only insertion and frame shift muta-
tion reported at exon 10 so far.
Conclusions
In conclusion, to our knowledge, this mutation has not
been reported before. Therefore, we think the c.2330dupG
(p.Gln778Serfs*4) mutation should be listed in the MEFV
sequence variants of FMF in databases. In order to identify
specific phenotype/genotype correlations exactly, the no-
vel mutation and its relationship should be confirmed by
studying homozygous individuals for this mutation and by
sequencing the MEFV gene completely to rule out other
possible mutations.
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